NEW YORK, Jan. 5, 2011 /PRNewswire-Asia/ — Dongsheng
Pharmaceutical International Co., Ltd. (the “Company”) (OTC
DNGH) announced today that it has obtained the exclusive sales
rights of Thymosin Alpha 1 Injection in 19 provinces in China from
Shanghai Biochemistry Pharmaceutical Co. I.
The State Food and Drug Administration of China (the “SFDA”)
approved the manufacturing permit of Thymosin Alpha 1 Injection for
Shanghai Biochemistry Pharmaceutical Co. I on June 29, 2010.
Immediately after such approval, Shanghai Biochemistry submitted
the manufactured samples to the SFDA for quality check, which is a
necessary step to receive final approval for mass manufacturing. We
expect that the samples will pass the quality check in the next 3-6
months, at which time Thymosin Alpha 1 Injection will be granted
final approval for mass manufacturing.
Thymosin Alpha 1 Injection is an immune modifier that has been
proven to be effective in the treatment of chronic hepatitis B,
acute severe hepatitis, adjuvant therapy for tumor and immuno
compromised diseases. Thymosin Alpha 1 Injection has been admitted
into the China National Basic Medicine Coverage List, thereby
making it more affordable to consumers and potentially increasing
its demand. In June 2010, Dongsheng commenced a marketing
campaign for Thymosin Alpha 1 Injection within its sales and
distribution network, and the response so far from potential
customers has been promising.
Mr. Zhu XiaoDong, CEO of Dongsheng Pharmaceutical International,
stated that, “Thymosin Alpha 1 is a high value and high margin
medicine. Obtaining exclusive sales rights for this product
in 19 provinces represents another milestone that Dongsheng
Pharmaceutical has accomplished since it went public in March
About Dongsheng Pharmaceutical International Co.,
Headquartered in Cheng